drugset / Trial / NCT00384969
Sorafenib and RAD001 Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of the phase I part of the study is to determine the maximum tolerated dose and dose limiting toxicities of the combination of RAD001 and sorafenib in patients with untreated metastatic kidney cancer.
Timeline
- Start
- 2006-10
- Primary completion
- 2013-12
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |